{"doc_id": "si-2025-0351-reg-1", "parent_doc_id": "si-2025-0351", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 351 of 2025", "title": "to in subsection (8) of section 36 and subsection (7) of section 51 of that Act", "year": 2025, "heading": "These Regulations may be cited as the Data Protection Act 2018", "text_raw": "1. \nThese Regulations may be cited as the Data Protection Act 2018 \n(Section 51(3)) (Inquiry into the Licensing and Use of Sodium Valproate in \nWomen of Child-Bearing Potential in the State) Regulations 2025. \n\nDefinitions", "text_norm": "1 regulation may cited data protection act 2018 (section 51(3)) (inquiry licensing use sodium valproate woman child-bearing potential state) regulation 2025 definition", "start_char": 1145, "end_char": 1370, "source_path": "downloads\\2025\\2025_0351.pdf", "extraction_method": "pdfminer", "checksum": "sha256:31f99f0228de7c7750682a9ce07863f590a3f68d11d3e516c8eab7a835698ac3", "cross_refs": []}
{"doc_id": "si-2025-0351-reg-2", "parent_doc_id": "si-2025-0351", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 351 of 2025", "title": "to in subsection (8) of section 36 and subsection (7) of section 51 of that Act", "year": 2025, "heading": "In these Regulations –", "text_raw": "2. \n\nIn these Regulations – \n\n“Act of 2018” means the Data Protection Act 2018 (No. 7 of 2018); \n\n“inquiry” means the inquiry into the licensing and use of sodium valproate in \nwomen of child-bearing potential in the State, approved by decision of the \nGovernment on 11 July 2023; \n\n“inquiry chair” means the person appointed by the Minister to conduct the \ninquiry and provide a final report to the Minister; \n\n“member of staff of the inquiry” means persons appointed by or working \nunder the direction of the inquiry chair and in support of the processes of the \ninquiry; \n\n“Minister” means the Minister for Health; \n\n“relevant person” means – \n\n(a) \n\nthe inquiry chair, \n\n(b) \n\ncounsel for the inquiry, \n\n(c) \n\n(d) \n\n(e) \n\na legal advisor to the inquiry chair, \n\na member of staff of the inquiry, \n\na clinical psychologist providing services to the inquiry chair \nin connection with the inquiry, \n\n(f) \n\nthe Minister, and \n\nNotice of the making of this Statutory Instrument was published in \n\"Iris Oifigiúil\" of 25th July, 2025. \n\n \n \n \n \n\f[351] 3 \n\n(g) \n\nany other person acting for, appointed by or working under the \ndirection of the inquiry chair or the Minister in connection with \nthe inquiry; \n\n“special categories of personal data” has the meaning assigned to it by section \n2 of the Act of 2018; \n\n“terms of reference” means the terms of reference of the inquiry, which terms \nare set out in the Schedule. \n\nProcessing of special categories of personal data for reasons of \nsubstantial public interest", "text_norm": "2 regulation - act 2018 mean data protection act 2018 (no 7 2018) inquiry mean inquiry licensing use sodium valproate woman child-bearing potential state approved decision government 11 july 2023 inquiry chair mean person appointed minister conduct inquiry provide final report minister member staff inquiry mean person appointed working direction inquiry chair support process inquiry minister mean minister health relevant person mean - (a) inquiry chair (b) counsel inquiry (c) (d) (e) legal advisor inquiry chair member staff inquiry clinical psychologist providing service inquiry chair connection inquiry (f) minister notice making statutory instrument published iris oifigiuil 25th july 2025 351 3 (g) person acting appointed working direction inquiry chair minister connection inquiry special category personal data meaning assigned section 2 act 2018 term reference mean term reference inquiry term set schedule processing special category personal data reason substantial public interest", "start_char": 1370, "end_char": 2886, "source_path": "downloads\\2025\\2025_0351.pdf", "extraction_method": "pdfminer", "checksum": "sha256:31f99f0228de7c7750682a9ce07863f590a3f68d11d3e516c8eab7a835698ac3", "cross_refs": []}
{"doc_id": "si-2025-0351-reg-3", "parent_doc_id": "si-2025-0351", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 351 of 2025", "title": "to in subsection (8) of section 36 and subsection (7) of section 51 of that Act", "year": 2025, "heading": "3. Subject to the Data Protection Regulation and the Act of 2018, the", "text_raw": "3. Subject to the Data Protection Regulation and the Act of 2018, the \nprocessing by a relevant person of special categories of personal data is \nauthorised only in so far as is necessary for, and proportionate to, the \nsubstantial public interest referred to in Regulation 4. \n\nSubstantial public interest", "text_norm": "3 subject data protection regulation act 2018 processing relevant person special category personal data authorised far necessary proportionate substantial public interest referred regulation 4 substantial public interest", "start_char": 2886, "end_char": 3195, "source_path": "downloads\\2025\\2025_0351.pdf", "extraction_method": "pdfminer", "checksum": "sha256:31f99f0228de7c7750682a9ce07863f590a3f68d11d3e516c8eab7a835698ac3", "cross_refs": []}
{"doc_id": "si-2025-0351-reg-4", "parent_doc_id": "si-2025-0351", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 351 of 2025", "title": "to in subsection (8) of section 36 and subsection (7) of section 51 of that Act", "year": 2025, "heading": "4. For the purposes of Regulation 3, “substantial public interest” means", "text_raw": "4. For the purposes of Regulation 3, “substantial public interest” means \nthe performance by the inquiry of the functions for which the inquiry chair \nwas appointed to inquire into, report and make such findings and \nrecommendations as the inquiry chair sees fit to the Minister under the terms \nof reference. \n\nJoint controllers of special categories of personal data", "text_norm": "4 purpose regulation 3 substantial public interest mean performance inquiry function inquiry chair appointed inquire report make finding recommendation inquiry chair see fit minister term reference joint controller special category personal data", "start_char": 3195, "end_char": 3566, "source_path": "downloads\\2025\\2025_0351.pdf", "extraction_method": "pdfminer", "checksum": "sha256:31f99f0228de7c7750682a9ce07863f590a3f68d11d3e516c8eab7a835698ac3", "cross_refs": []}
{"doc_id": "si-2025-0351-reg-5", "parent_doc_id": "si-2025-0351", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 351 of 2025", "title": "to in subsection (8) of section 36 and subsection (7) of section 51 of that Act", "year": 2025, "heading": "5. For the purposes of these Regulations and within the meaning of the", "text_raw": "5. For the purposes of these Regulations and within the meaning of the \nData Protection Regulation and the Act of 2018, the Minister and the inquiry \nchair are joint controllers of special categories of personal data provided to \nthe inquiry. \n\nPersons to whom special categories of personal data may be disclosed", "text_norm": "5 purpose regulation within meaning data protection regulation act 2018 minister inquiry chair joint controller special category personal data provided inquiry person special category personal data may disclosed", "start_char": 3566, "end_char": 3882, "source_path": "downloads\\2025\\2025_0351.pdf", "extraction_method": "pdfminer", "checksum": "sha256:31f99f0228de7c7750682a9ce07863f590a3f68d11d3e516c8eab7a835698ac3", "cross_refs": []}
{"doc_id": "si-2025-0351-reg-6", "parent_doc_id": "si-2025-0351", "section_id": "reg-6", "section_label": "Regulation 6.", "si_number": "S.I. No. 351 of 2025", "title": "to in subsection (8) of section 36 and subsection (7) of section 51 of that Act", "year": 2025, "heading": "6. Special categories of personal data may be disclosed to a relevant", "text_raw": "6. Special categories of personal data may be disclosed to a relevant \nperson in accordance with such policies and procedures as may be provided \nfor under Regulation 7. \n\nSuitable and specific measures to be taken to safeguard fundamental \nrights and freedoms of a data subject in processing special categories of \npersonal data authorised by these Regulations", "text_norm": "6 special category personal data may disclosed relevant person accordance policy procedure may provided regulation 7 suitable specific measure taken safeguard fundamental right freedom data subject processing special category personal data authorised regulation", "start_char": 3882, "end_char": 4246, "source_path": "downloads\\2025\\2025_0351.pdf", "extraction_method": "pdfminer", "checksum": "sha256:31f99f0228de7c7750682a9ce07863f590a3f68d11d3e516c8eab7a835698ac3", "cross_refs": []}
{"doc_id": "si-2025-0351-reg-7", "parent_doc_id": "si-2025-0351", "section_id": "reg-7", "section_label": "Regulation 7.", "si_number": "S.I. No. 351 of 2025", "title": "to in subsection (8) of section 36 and subsection (7) of section 51 of that Act", "year": 2025, "heading": "7. The inquiry chair shall, for the purposes of safeguarding the", "text_raw": "7. The inquiry chair shall, for the purposes of safeguarding the \nfundamental rights and freedoms of a data subject in processing special \ncategories of personal data in accordance with these Regulations, take the \nfollowing suitable and specific measures: \n\n \n \n \n \n \n\f4 [351] \n\n(a) \n\nprepare and implement policies and procedures for the \nprocessing of special categories of personal data under these \nRegulations, including in relation to the following: \n\n(i) \n\n(ii) \n\n(iii) \n\n(iv) \n\nthe use of secure storage, passwords, encryption, logging \nmechanisms and other methods to ensure that the special \ncategories of personal data can only be accessed by a \nrelevant person authorised by the inquiry chair to access \nthat data; \n\nthe use of controls to ensure that special categories of \npersonal data are only disclosed to a relevant person \nauthorised by the inquiry chair, or who are entitled or \npermitted by law, to receive that data; \n\nthe determination of appropriate storage periods for \nspecial categories of personal data or classes of special \ncategories of personal data; \n\nthe treatment of special categories of personal data or \nclasses of special categories of personal data at the \nexpiry of the storage periods referred to in subparagraph \n(iii); \n\n(v) \n\nthe erasure of special categories of personal data; \n\n(vi) ensure that relevant persons have undertaken to maintain \nthe integrity and confidentiality of the special categories \nof personal data or are under an appropriate statutory \nobligation to do so; \n\n(vii) the designation by the inquiry chair of a data protection \n\nofficer for the purposes of these Regulations; \n\n(viii) data minimisation, including the use of anonymisation \n\nand pseudonymisation, where appropriate; \n\n(b) without prejudice to the generality of paragraph (a), take such \nother measures as the inquiry chair considers appropriate to \nensure that – \n\n(i) \n\nspecial categories of personal data are processed under \nthese Regulations to the extent only that such processing \nis strictly necessary, and \n\n(ii) on a regular basis, an assessment is made by the inquiry \nchair of the risks to the fundamental rights and freedoms \nof data subjects in respect of whom special categories of \npersonal data are processed under these Regulations by \nreason of such processing; \n\n(c) \n\nensure that the policies and procedures referred to in paragraph \n(a) and any measures referred to in paragraph (b) are reviewed \non a regular basis, and, as the inquiry chair considers it \nappropriate to do so, updated. \n\n \n \n\f[351] 5 \n\nSchedule \nInquiry into the licensing and use of sodium valproate in women of \nchild-bearing potential in the State \n\nTerms of Reference \n\nPurpose and focus of the Inquiry \n\nThe purpose of the inquiry is as follows: \n\n• To provide a voice to persons with a diagnosis of foetal valproate \nspectrum disorder (FVSD), or progressing through the diagnostic \npathway, their mothers and other family members. \n\n• To document the regulation of sodium valproate in the State from \ninitial licensing until the present day and the corresponding practices \nand controls in place relating to the prescribing and dispensing of this \nproduct to women of child-bearing potential throughout this time. \n\n• To develop a timeline of significant developments in the scientific \n\nknowledge relating to the teratogenicity of sodium valproate. \n\n• To assess the Irish health system’s current capacity to respond, \ndisseminate and implement measures that address safety issues \nrelating to use of sodium valproate in women of child-bearing \npotential, and to provide recommendations regarding same, with \nconsideration of relevance to other anti-seizure medications (ASMs). \n\n• To assess the adequacy of services and supports currently provided to \nthose diagnosed with FVSD and their caregivers, and to provide \nrecommendations regarding same if identified. \n\nReview Phase \n\n• Establish a timeline on the licensing and use of sodium valproate in \nwomen of child-bearing potential and the emergence of evidence \nregarding its teratogenicity since it was first licensed in the State until \nthe present day by review of the following: \n\n International Classification of Diseases, Version 11, as adopted by the WHO Assembly \nin March 2019, defines Fetal Valproate Spectrum Disorder (code LD2F.03 ) as: Fetal \nvalproate spectrum disorder (FVSD) and Fetal valproate syndrome (FVS) describe the range \nof signs and symptoms which occur as a consequence of exposure to sodium valproate or \nvalproic acid in the womb. A wide range of physical anomalies occur at increased frequency, \nincluding spina bifida, major and minor limb abnormalities, oral clefting, cardiac defects, \nhypospadias, and joint laxity. A characteristic pattern of facial dysmorphism is frequently \npresent, especially notable in early childhood. Neurodevelopmental problems including \nreduced IQ, poorer language and motor development, increased rates of autistic spectrum \ndisorder and attention deficit hyperactivity disorder are observed in up to 40% of those \nexposed. Vision problems such as myopia and astigmatism are also common. Risks are dose \ndependent and the impact on the brain may be seen at lower doses than those required for \nphysical development alterations. \n\n \n \n \n \n\f6 [351]", "text_norm": "7 inquiry chair shall purpose safeguarding fundamental right freedom data subject processing special category personal data accordance regulation take following suitable specific measure 4 351 (a) prepare implement policy procedure processing special category personal data regulation including relation following (i) (ii) (iii) (iv) use secure storage password encryption logging mechanism method ensure special category personal data accessed relevant person authorised inquiry chair access data use control ensure special category personal data disclosed relevant person authorised inquiry chair entitled permitted law receive data determination appropriate storage period special category personal data class special category personal data treatment special category personal data class special category personal data expiry storage period referred subparagraph (iii) (v) erasure special category personal data (vi) ensure relevant person undertaken maintain integrity confidentiality special category personal data appropriate statutory obligation (vii) designation inquiry chair data protection officer purpose regulation (viii) data minimisation including use anonymisation pseudonymisation appropriate (b) without prejudice generality paragraph (a) take measure inquiry chair considers appropriate ensure - (i) special category personal data processed regulation extent processing strictly necessary (ii) regular basis assessment made inquiry chair risk fundamental right freedom data subject respect special category personal data processed regulation reason processing (c) ensure policy procedure referred paragraph (a) measure referred paragraph (b) reviewed regular basis inquiry chair considers appropriate updated 351 5 schedule inquiry licensing use sodium valproate woman child-bearing potential state term reference purpose focus inquiry purpose inquiry follows provide voice person diagnosis foetal valproate spectrum disorder (fvsd) progressing diagnostic pathway mother family member document regulation sodium valproate state initial licensing present day corresponding practice control place relating prescribing dispensing product woman child-bearing potential throughout time develop timeline significant development scientific knowledge relating teratogenicity sodium valproate ass irish health system current capacity respond disseminate implement measure address safety issue relating use sodium valproate woman child-bearing potential provide recommendation regarding consideration relevance anti-seizure medication (asms) ass adequacy service support currently provided diagnosed fvsd caregiver provide recommendation regarding identified review phase establish timeline licensing use sodium valproate woman child-bearing potential emergence evidence regarding teratogenicity since first licensed state present day review following international classification disease version 11 adopted assembly march 2019 defines fetal valproate spectrum disorder (code ld2f.03 ) fetal valproate spectrum disorder (fvsd) fetal valproate syndrome (fvs) describe range sign symptom occur consequence exposure sodium valproate valproic acid womb wide range physical anomaly occur increased frequency including spina bifida major minor limb abnormality oral clefting cardiac defect hypospadias joint laxity characteristic pattern facial dysmorphism frequently present especially notable early childhood neurodevelopmental problem including reduced iq poorer language motor development increased rate autistic spectrum disorder attention deficit hyperactivity disorder observed 40 exposed vision problem myopia astigmatism also common risk dose dependent impact brain may seen lower dos required physical development alteration 6 351", "start_char": 4246, "end_char": 9547, "source_path": "downloads\\2025\\2025_0351.pdf", "extraction_method": "pdfminer", "checksum": "sha256:31f99f0228de7c7750682a9ce07863f590a3f68d11d3e516c8eab7a835698ac3", "cross_refs": []}
{"doc_id": "si-2025-0351-reg-1", "parent_doc_id": "si-2025-0351", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 351 of 2025", "title": "to in subsection (8) of section 36 and subsection (7) of section 51 of that Act", "year": 2025, "heading": "1. Documentation on the licensing and regulation of sodium", "text_raw": "1. Documentation on the licensing and regulation of sodium \nvalproate for use in women of child-bearing potential in the State \nand associated safety reports.", "text_norm": "1 documentation licensing regulation sodium valproate use woman child-bearing potential state associated safety report", "start_char": 9547, "end_char": 9708, "source_path": "downloads\\2025\\2025_0351.pdf", "extraction_method": "pdfminer", "checksum": "sha256:31f99f0228de7c7750682a9ce07863f590a3f68d11d3e516c8eab7a835698ac3", "cross_refs": []}
{"doc_id": "si-2025-0351-reg-2", "parent_doc_id": "si-2025-0351", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 351 of 2025", "title": "to in subsection (8) of section 36 and subsection (7) of section 51 of that Act", "year": 2025, "heading": "2. Reports and studies that have been conducted regarding the use", "text_raw": "2. Reports and studies that have been conducted regarding the use \nand impact in the State of sodium valproate in women of childbearing potential.", "text_norm": "2 report study conducted regarding use impact state sodium valproate woman childbearing potential", "start_char": 9708, "end_char": 9857, "source_path": "downloads\\2025\\2025_0351.pdf", "extraction_method": "pdfminer", "checksum": "sha256:31f99f0228de7c7750682a9ce07863f590a3f68d11d3e516c8eab7a835698ac3", "cross_refs": []}
{"doc_id": "si-2025-0351-reg-3", "parent_doc_id": "si-2025-0351", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 351 of 2025", "title": "to in subsection (8) of section 36 and subsection (7) of section 51 of that Act", "year": 2025, "heading": "3. Any formal notifications alerting of safety concerns relating to", "text_raw": "3. Any formal notifications alerting of safety concerns relating to \nthe use of this medicine in women of child-bearing potential.", "text_norm": "3 formal notification alerting safety concern relating use medicine woman child-bearing potential", "start_char": 9857, "end_char": 9990, "source_path": "downloads\\2025\\2025_0351.pdf", "extraction_method": "pdfminer", "checksum": "sha256:31f99f0228de7c7750682a9ce07863f590a3f68d11d3e516c8eab7a835698ac3", "cross_refs": []}
{"doc_id": "si-2025-0351-reg-4", "parent_doc_id": "si-2025-0351", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 351 of 2025", "title": "to in subsection (8) of section 36 and subsection (7) of section 51 of that Act", "year": 2025, "heading": "4. Any guidance documents issued within the state for the use of this", "text_raw": "4. Any guidance documents issued within the state for the use of this \n\nmedicine in women of child-bearing potential.", "text_norm": "4 guidance document issued within state use medicine woman child-bearing potential", "start_char": 9990, "end_char": 10110, "source_path": "downloads\\2025\\2025_0351.pdf", "extraction_method": "pdfminer", "checksum": "sha256:31f99f0228de7c7750682a9ce07863f590a3f68d11d3e516c8eab7a835698ac3", "cross_refs": []}
{"doc_id": "si-2025-0351-reg-5", "parent_doc_id": "si-2025-0351", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 351 of 2025", "title": "to in subsection (8) of section 36 and subsection (7) of section 51 of that Act", "year": 2025, "heading": "5. Work completed by the EMA to reduce valproate exposure in", "text_raw": "5. Work completed by the EMA to reduce valproate exposure in \npregnancy, particularly reports and recommendations issued in \n2014 and 2018 and implementation of same in the State.", "text_norm": "5 work completed ema reduce valproate exposure pregnancy particularly report recommendation issued 2014 2018 implementation state", "start_char": 10110, "end_char": 10292, "source_path": "downloads\\2025\\2025_0351.pdf", "extraction_method": "pdfminer", "checksum": "sha256:31f99f0228de7c7750682a9ce07863f590a3f68d11d3e516c8eab7a835698ac3", "cross_refs": []}
{"doc_id": "si-2025-0351-reg-6", "parent_doc_id": "si-2025-0351", "section_id": "reg-6", "section_label": "Regulation 6.", "si_number": "S.I. No. 351 of 2025", "title": "to in subsection (8) of section 36 and subsection (7) of section 51 of that Act", "year": 2025, "heading": "6. Government commissioned reports published in the U.K. and", "text_raw": "6. Government commissioned reports published in the U.K. and \nother European jurisdictions concerning the use of sodium \nvalproate in women of child-bearing potential. \n\n• \n\nIssue and review questionnaires to stakeholders to support this \ncollation of information relating to sodium valproate. A list of \nsuggested stakeholders is given in Appendix 1. \n\nOral statements \n\n• Following assessment of written submissions and documents, invite \nindividuals diagnosed with FVSD, their mothers and other family \nmembers who wish to engage with the inquiry to provide oral \nstatements. \n\n• Document the impact and experience of sodium valproate on the lives \nof those affected - both the women prescribed valproate in pregnancy \nand those with a diagnosis of FVSD and their families. \n\n• At the Chair's discretion, other stakeholders may also be invited to \nattend oral sessions, in separate sittings to patients and their families. \n\n \n \n \n \n\f[351] 7 \n\nAssessment of current systems and recommendation for improvements \nif identified \n\n• Based on the documented experiences of women given during oral \nsessions and through written submissions, make recommendations as \nto how communication and discussion of risks may be improved for \nany woman prescribed sodium valproate. \n\n• Review current systems in place to ensure clear communication of \nrisks to, and obtainment of informed consent from, women of childbearing age who are prescribed sodium valproate. Make \nrecommendations for improvement if identified. \n\n• Review the controls in place regarding the prescribing and dispensing \nof sodium valproate to women of child-bearing age in the state \nincluding the adequacy of same to support implementation of the \napproved pregnancy prevention programme. Assess their adequacy \nand make recommendations as to how these controls can be improved \nif identified. \n\n• Consider the relevance of recommendations made to the use of other \n\nASMs in women of child-bearing potential. \n\n• Being cognisant of the systems already in place for the dissemination \nof medicines safety information, make recommendations as to how \nthese systems may be improved where risks are identified for use of \nASMs during pregnancy. \n\n• Consider the adequacy of services and supports currently provided to \nFVSD patients and their families, considering both statements \nsubmitted and information gathered by the inquiry. \n\n• Make any other recommendations considered appropriate by the Chair \n\nto support those with a diagnosis of FVSD. \n\nDeliverables and Associated Schedule \n\n• \n\n• \n\nInterim report to be provided to Minister within 6 months of the \ncommencement date of the inquiry, with update to those who have \nparticipated in the inquiry as relevant. \n\nInterim report will outline any assessments and recommendations \nmade to that point, highlighting issues for immediate action that may \nbecome apparent during the conduct of the review. \n\n• At this time, agree a date for provision of the final report to the \nMinister for Health, ideally within 12 months but not later than 18 \nmonths after the commencement of the inquiry. No further extension \nbeyond 3 months will be given beyond this agreed date. \n\nSubject to legal advice, stakeholders, including individuals and families who \nprovided oral statements will be provided with a confidential copy of the \nfinal report by the Minister in advance of publication. \n\n \n \n\f8 [351] \n\nSuggested list of Stakeholders \n\nThe Chair may invite submissions from a range of stakeholders, including but \nnot limited to: \n\nStakeholder \n\nIndividual bodies (if applicable) \n\nIndividuals and families with a \ndiagnosis of FVSD \n\n• HSE \n\n• OACS \n\n• Epilepsy Ireland \n\nOrganisation for Anticonvulsant \nSyndrome (OACS) Ireland \n\nn/a \n\nHealth Products Regulatory Authority \n(HPRA) \n\nn/a \n\nThe Health Service Executive (HSE) \n\nn/a \n\nThe Department of Health \n\nSanofi \n\nn/a \n\nn/a \n\nPrescribers of sodium valproate \n\n• \n\nIrish Medical Organisation \n\n• Medical Council \n\n• \n\nIrish College of General \nPractitioners \n\n• HSE Clinical Leads for \nEpilepsy and Neurology \n\n• College of Psychiatrists of \n\nIreland \n\nThe Pharmaceutical Society of Ireland \n\nn/a \n\nEpilepsy Ireland \n\nDisability Federation of Ireland \n\nn/a \n\nn/a \n\n \n \n \n \n \n\f[351] 9 \n\nForm and structure of inquiry proposed \n\nThe proposed non-statutory inquiry will be structured according to three \nseparate strands. The first strand will create a timeline for the use of sodium \nvalproate in the State in women of child-bearing potential including \ninformation on regulation, prescribing, dispensing and safety information \nissued. \n\nThe second strand of the inquiry will enable oral statements to be given by \nindividuals diagnosed with FVSD, their mothers and other family members \nwho may wish to participate in this inquiry. This will provide mothers, \npatients and their families with an opportunity to tell their story. These \nstatements will be considered in the third phase by the Chair in developing \nrecommendations on supports for patients. \n\nOther stakeholders may also be invited to provide statements in separate \nsessions. All sessions will be held in private. \n\nThe third strand will involve the following: \n\n• An assessment of the current systems in place to respond, disseminate \nand implement measures that address safety issues relating to use of \nsodium valproate in women of child-bearing potential and to provide \nrecommendations for improvement of systems if identified. \n\n• Development of other recommendations based on the Chair’s \n\nassessment of:", "text_norm": "6 government commissioned report published u.k european jurisdiction concerning use sodium valproate woman child-bearing potential issue review questionnaire stakeholder support collation information relating sodium valproate list suggested stakeholder given appendix 1 oral statement following assessment written submission document invite individual diagnosed fvsd mother family member wish engage inquiry provide oral statement document impact experience sodium valproate life affected - woman prescribed valproate pregnancy diagnosis fvsd family chair discretion stakeholder may also invited attend oral session separate sitting patient family 351 7 assessment current system recommendation improvement identified based documented experience woman given oral session written submission make recommendation communication discussion risk may improved woman prescribed sodium valproate review current system place ensure clear communication risk obtainment informed consent woman childbearing age prescribed sodium valproate make recommendation improvement identified review control place regarding prescribing dispensing sodium valproate woman child-bearing age state including adequacy support implementation approved pregnancy prevention programme ass adequacy make recommendation control improved identified consider relevance recommendation made use asms woman child-bearing potential cognisant system already place dissemination medicine safety information make recommendation system may improved risk identified use asms pregnancy consider adequacy service support currently provided fvsd patient family considering statement submitted information gathered inquiry make recommendation considered appropriate chair support diagnosis fvsd deliverable associated schedule interim report provided minister within 6 month commencement date inquiry update participated inquiry relevant interim report outline assessment recommendation made point highlighting issue immediate action may become apparent conduct review time agree date provision final report minister health ideally within 12 month later 18 month commencement inquiry extension beyond 3 month given beyond agreed date subject legal advice stakeholder including individual family provided oral statement provided confidential copy final report minister advance publication 8 351 suggested list stakeholder chair may invite submission range stakeholder including limited stakeholder individual body (if applicable) individual family diagnosis fvsd hse oacs epilepsy ireland organisation anticonvulsant syndrome (oacs) ireland n health product regulatory authority (hpra) n health service executive (hse) n department health sanofi n n prescribers sodium valproate irish medical organisation medical council irish college general practitioner hse clinical lead epilepsy neurology college psychiatrist ireland pharmaceutical society ireland n epilepsy ireland disability federation ireland n n 351 9 form structure inquiry proposed proposed non-statutory inquiry structured according three separate strand first strand create timeline use sodium valproate state woman child-bearing potential including information regulation prescribing dispensing safety information issued second strand inquiry enable oral statement given individual diagnosed fvsd mother family member may wish participate inquiry provide mother patient family opportunity tell story statement considered third phase chair developing recommendation support patient stakeholder may also invited provide statement separate session session held private third strand involve following assessment current system place respond disseminate implement measure address safety issue relating use sodium valproate woman child-bearing potential provide recommendation improvement system identified development recommendation based chair assessment", "start_char": 10292, "end_char": 15832, "source_path": "downloads\\2025\\2025_0351.pdf", "extraction_method": "pdfminer", "checksum": "sha256:31f99f0228de7c7750682a9ce07863f590a3f68d11d3e516c8eab7a835698ac3", "cross_refs": []}
{"doc_id": "si-2025-0351-reg-1", "parent_doc_id": "si-2025-0351", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 351 of 2025", "title": "to in subsection (8) of section 36 and subsection (7) of section 51 of that Act", "year": 2025, "heading": "1. relevance of findings regarding current control systems for", "text_raw": "1. relevance of findings regarding current control systems for \nsodium valproate for other ASMs that may be used in women \nof child-bearing potential, particularly if new evidence emerges.", "text_norm": "1 relevance finding regarding current control system sodium valproate asms may used woman child-bearing potential particularly new evidence emerges", "start_char": 15832, "end_char": 16023, "source_path": "downloads\\2025\\2025_0351.pdf", "extraction_method": "pdfminer", "checksum": "sha256:31f99f0228de7c7750682a9ce07863f590a3f68d11d3e516c8eab7a835698ac3", "cross_refs": []}
{"doc_id": "si-2025-0351-reg-2", "parent_doc_id": "si-2025-0351", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 351 of 2025", "title": "to in subsection (8) of section 36 and subsection (7) of section 51 of that Act", "year": 2025, "heading": "2. services and supports for those diagnosed with FVSD", "text_raw": "2. services and supports for those diagnosed with FVSD \n\nas informed by information collated during the inquiry. \n\nThe scheduling of work across and within these strands will be at the \ndiscretion of the Chair of the inquiry. The Chair will be required to highlight \nany issues encountered in obtaining necessary documentation to the Minister, \nshould they arise during the inquiry. A record of this will be included in the \nreports prepared by the Chair. \n\nData Protection and Records Management \n\nThe inquiry should operate to the highest and most appropriate standards of \ndata protection and records management. The Chair will act as data processor, \nand, with the Minister for Health, as joint data controller. The Minister may \nmake regulations to enable the inquiry to process personal data and special \ncategories of data. A Data Protection Impact Assessment will be put in place. \nRecords created in the course of the conduct of the inquiry will be available \nto the Minister for Health. However, at the cessation of the inquiry, decisions \nwill be made regarding the disposal or retention of records, balancing data \nsubject rights with the Minister's obligations under the National Archives Act \n1986 and Regulations 1988. \n\n \n \n\f10 [351] \n\nSupporting Patient & Family Participation \n\nRegarding patients and families who choose to engage with the inquiry, it is \nacknowledged that this will be a difficult experience for many. It is considered \nby the Minister for Health that the participants, for reasons of their health and \nwellbeing, or due to their care commitments, or due to practical matters \narising from their circumstances, may encounter barriers to participation. \n\nThe Minister for Health will ask the Chair to examine the provision of \nappropriate supports to enable participation. Counselling supports, a modest \nex-gratia payment, or reasonable support to access other professional advice, \ncould be considered by the Chair. While supports should be specific to the \nneeds of the cohort of individuals participating in this inquiry, the Minister \nwill ask the Chair to consider the supports provided to participants in the \nScally Inquiry, and whether a similar process could apply in this context. \n\nAny such supports will be put in place on a one-off basis, and are specific to \nthis non-statutory inquiry, it is not intended to set a precedent. However, in \nkeeping with the independence of their role, the Chair will make all final \ndecisions as to how best to establish and encourage participation with the \ninquiry. Further information on any supports being provided would be issued \nto participants upon application to the inquiry. \n\nAs part of the establishment of the inquiry, the Chair will develop a strategic \nawareness campaign with the aim of achieving a high level of participation in \nthe inquiry. \n\nAppointment of a Chair \n\nThe Chair will be appointed by the Minister. The Chair will not have any \nconflicts of interest which could be seen as undermining the independence or \nintegrity of the inquiry. The Chair must be an appropriate person who is \ncompetent to carry out and manage the process of the inquiry in a timely \nmanner, while giving due regard to the primacy of a person-centred, fair and \nindependent process, and giving weight to all stakeholders and participants. \nThe Chair must have familiarity with the Health and Social Care services in \nthe State. The Chair may require, and must consider, independent and expert \nadvice in relation to some elements of the inquiry. The Chair must be able to \nevidence experience appropriate to the conduct of a non-statutory inquiry. \n\nRole of the Chair \n\n• The Chair shall conduct the inquiry independently in accordance with \n\nthe Terms of Reference as set out above, and will: \n\n• With initial support from Department of Health, establish and \n\noperationalise the inquiry \n\n• With Department of Health support, and in consultation with \npatient groups, the Chair will provide appropriate supports to \nfacilitate the participation of patients and their families with \nthis inquiry. In keeping with the independence of the role, the \n\n \n \n\f[351] 11 \n\nChair will make all final decisions as to how best to establish \nand encourage participation with the inquiry \n\n• Develop a strategic awareness campaign \n\nto promote \n\nparticipation in the inquiry \n\n• Conduct the review phase \n\n• Gather and assess statements from affected families \n\n• Gather and assess information and statements from other \n\nidentified stakeholders \n\n• Assess \n\ncurrent \n\nsystems \n\nand \n\nsupports \n\nand make \n\nrecommendations if identified \n\n• Produce the interim and final reports \n\n• The Chair will identify and set out such support and advice as they \ndeem necessary for the conduct of the inquiry, to be finalised by \nagreement with the Minister for Health \n\n• Within the bounds of the Terms of Reference, the Chair will gather \nsuch information as they require in order to conduct an independent, \nfair and rigorous process \n\n• \n\nIn order to gather information relevant to the inquiry, the Chair shall \nact as a joint Data Controller with the Minister for Health, subject to \nan agreement to be put in place. \n\n• The Chair will adhere to the legal basis for processing personal data \nand special categories of data as set out in the Data Protection Impact \nAssessment for the inquiry \n\n• The Chair will ensure that records formed as part of the conduct of the \ninquiry are managed appropriately, with arrangements made for \nretention or destruction of records as appropriate \n\nImplementation of Recommendations \n\nThe Department is committed to considering all recommendations made in \nthe final report. After the final report is submitted to the Minister, a working \ngroup consisting of relevant stakeholders will be established within 3 months \nto provide quarterly progress reports on the implementation of accepted \nrecommendations of the inquiry. \n\nGIVEN under my Official Seal, \n\n21 July, 2025. \n\nJENNIFER CARROLL MACNEILL, \n\nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n\f12 [351]", "text_norm": "2 service support diagnosed fvsd informed information collated inquiry scheduling work across within strand discretion chair inquiry chair required highlight issue encountered obtaining necessary documentation minister arise inquiry record included report prepared chair data protection record management inquiry operate highest appropriate standard data protection record management chair act data processor minister health joint data controller minister may make regulation enable inquiry process personal data special category data data protection impact assessment put place record created course conduct inquiry available minister health however cessation inquiry decision made regarding disposal retention record balancing data subject right minister obligation national archive act 1986 regulation 1988 10 351 supporting patient family participation regarding patient family choose engage inquiry acknowledged difficult experience many considered minister health participant reason health wellbeing due care commitment due practical matter arising circumstance may encounter barrier participation minister health ask chair examine provision appropriate support enable participation counselling support modest ex-gratia payment reasonable support access professional advice could considered chair support specific need cohort individual participating inquiry minister ask chair consider support provided participant scally inquiry whether similar process could apply context support put place one-off basis specific non-statutory inquiry intended set precedent however keeping independence role chair make final decision best establish encourage participation inquiry information support provided would issued participant upon application inquiry part establishment inquiry chair develop strategic awareness campaign aim achieving high level participation inquiry appointment chair chair appointed minister chair conflict interest could seen undermining independence integrity inquiry chair must appropriate person competent carry manage process inquiry timely manner giving due regard primacy person-centred fair independent process giving weight stakeholder participant chair must familiarity health social care service state chair may require must consider independent expert advice relation element inquiry chair must able evidence experience appropriate conduct non-statutory inquiry role chair chair shall conduct inquiry independently accordance term reference set initial support department health establish operationalise inquiry department health support consultation patient group chair provide appropriate support facilitate participation patient family inquiry keeping independence role 351 11 chair make final decision best establish encourage participation inquiry develop strategic awareness campaign promote participation inquiry conduct review phase gather ass statement affected family gather ass information statement identified stakeholder ass current system support make recommendation identified produce interim final report chair identify set support advice deem necessary conduct inquiry finalised agreement minister health within bound term reference chair gather information require order conduct independent fair rigorous process order gather information relevant inquiry chair shall act joint data controller minister health subject agreement put place chair adhere legal basis processing personal data special category data set data protection impact assessment inquiry chair ensure record formed part conduct inquiry managed appropriately arrangement made retention destruction record appropriate implementation recommendation department committed considering recommendation made final report final report submitted minister working group consisting relevant stakeholder established within 3 month provide quarterly progress report implementation accepted recommendation inquiry given official seal 21 july 2025 jennifer carroll macneill minister health 12 351", "start_char": 16023, "end_char": 22082, "source_path": "downloads\\2025\\2025_0351.pdf", "extraction_method": "pdfminer", "checksum": "sha256:31f99f0228de7c7750682a9ce07863f590a3f68d11d3e516c8eab7a835698ac3", "cross_refs": []}
{"doc_id": "si-2025-0351-explanatory-note", "parent_doc_id": "si-2025-0351", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 351 of 2025", "title": "to in subsection (8) of section 36 and subsection (7) of section 51 of that Act", "year": 2025, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThe purpose of these Regulations is to enable the commencement of the nonstatutory inquiry into the licensing and use of sodium valproate in women of \nchild-bearing potential in the State by providing a legislative base for the \ncontrolling and processing of special categories of personal data for reasons \nof substantial public interest by the joint data controllers. \n\n \n \n \n \n \n \n\f[351] 13 \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€3.50 \n\n(DH-595) 30. 7/25. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) purpose regulation enable commencement nonstatutory inquiry licensing use sodium valproate woman child-bearing potential state providing legislative base controlling processing special category personal data reason substantial public interest joint data controller 351 13 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur3.50 (dh-595) 30 7 25 propylon", "start_char": 22082, "end_char": 23075, "source_path": "downloads\\2025\\2025_0351.pdf", "extraction_method": "pdfminer", "checksum": "sha256:31f99f0228de7c7750682a9ce07863f590a3f68d11d3e516c8eab7a835698ac3", "cross_refs": []}
